With COVID-19 cases soaring across the US and worldwide, the need for a vaccine could not be greater. Here’s where we stand on vaccine development, including positive results from Pfizer’s trial.
Articles on Pfizer
Displaying 101 - 116 of 116 articles
Early analysis suggests this vaccine has an efficacy of over 90%. So if you took ten people who were going to get sick from COVID-19 and vaccinated them, only one would get sick.
Two more COVID-19 vaccines may now be on the cards for Australia, should they pass clinical trials. But, as with earlier vaccine deals, there are no guarantees.
So-called mRNA vaccines are among the frontrunners in the global race to design a COVID vaccine. But as a new technology, most nations, including Australia, lack the capacity to produce them at scale.
Our best shot at ending the pandemic is by achieving herd immunity through widespread use of a vaccine. But that won’t happen unless people believe it’s safe.
Instead of a global response to the pandemic, we’re seeing an outbreak of vaccine nationalism.
Studies repeatedly have shown that health care in general and the high cost of drugs in particular are among the top concerns of US voters. But with coronavirus, the issue may fade from prominence.
A group of America’s most powerful CEOs said companies should no longer merely focus on maximizing shareholder wealth. A business professor explains why it’s not a big deal.
Because we’re still not sure exactly what causes dementia, finding a treatment is difficult.
Pharmaceutical giant Pfizer has engaged in a series of paper transactions to create a A$936 million loss in Australia – effectively a billion-dollar exercise in avoiding tax.
The high cost of cancer drugs in South Africa has come under the spotlight with an investigation by the Competition Commission in the country.
Obama calls them insidious and others have described inversions as unpatriotic, but what they really do is show just how much of a mess the corporate tax code is.
The furore over US pharmaceuticals giant Pfizer’s attempted takeover of UK rival AstraZeneca continues. AstraZeneca has now rejected Pfizer’s “final” offer, as it says the proposed deal “undervalues the…
Pfizer is like Woody Allen’s famous shark. It has to keep moving or it will die. And the drug company seems unable to keep moving by any means other than acquisitions. Its all-time best-selling drug, Lipitor…
Those for whom Viagra is indispensable might be a little surprised that the ubiquitous blue, diamond-shaped pill was a chance discovery by a group of research pharmaceutical chemists at Pfizer’s research…
First it was the Pharmacy Guild’s deal with Blackmores that raised ethical concerns. Now it’s the Guild and Pfizer. Both deals involve undisclosed payments from drug companies to Guild subsidiaries to…
Top contributors
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Professor, The Children's Hospital at Westmead Clinical School and Sydney Infectious Diseases Institute, University of Sydney
-
Dean Faculty of Health Sciences and Professor of Vaccinology at University of the Witwatersrand; and Director of the SAMRC Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand
-
Professor of Medicine, University of Virginia
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professorial Fellow, University of Canberra
-
Instructor of Human Immunology, Emory University
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor, Infectious Diseases and Microbiology, The University of Queensland
-
Professor of Paediatrics and vaccinologist, Royal Childrens Hospital, University of Melbourne and Murdoch Childrens Research Institute (MCRI); Associate Dean International, University of Melbourne, Murdoch Children's Research Institute
-
Pharmacist and PhD Candidate, University of Sydney
-
Pediatric Infectious Diseases Fellow, University of Pittsburgh
-
Professor of Pharmaceutical Chemistry, Macquarie University
-
Professor of Business, University of Michigan